This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I read with great interest the article by Sarasin et al¹ in the October 9, 2000, issue of the ARCHIVES. The authors have performed a thorough analysis of the cost-effectiveness of emerging antiplatelet therapies. A review of their data, however, reveals a point that will be particularly important for North American physicians. The authors cite "current market prices" (which I assume represent prices in Switzerland and Germany) as their source for the daily costs of aspirin with or without dipyridamole, resulting in a daily cost of the aspirin/dipyridamole combination of $0.60. The average US wholesale price for this medication, however, is $1.47 for the 25 mg/200 mg formulation, or roughly $2.95 for the dosage analyzed in the study.² This is far outside the values used in their sensitivity analysis. The authors note that at a daily cost of $1.20 this regimen goes from a cost savings to a cost-effectiveness ratio . . . [Full Text of this Article]